Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of emicizumab in type 3 von Willebrand disease
NL-OMON60004Phase 3Recruiting
- Sponsor
- Roche
- Start
- Aug 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of emicizumab in Type 3 von Willebrand disease (3 arms), sponsored by Roche. Primary endpoint: Number of treated bleeds over time. Started Aug 2025; status: recruiting.
02
Drugs
emicizumab
03
Conditions
Type 3 von Willebrand disease
Beyond the preview
Go deeper on NL-OMON60004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60004.